Latest Structural Heart News

Edwards Lifesciences delivered stronger-than-expected third-quarter growth and lifted its full-year 2026 outlook, led by a sharp rise in mitral and tricuspid therapies. A US$220.2 million impairment charge remains a notable counterpoint to the upbeat operating performance.

Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.

Anteris Technologies Global Corp. has launched a $230 million equity offering alongside an $84 million private placement with Medtronic’s subsidiary, aiming to accelerate clinical trials and scale manufacturing of its innovative DurAVR Transcatheter Heart Valve.

Anteris Technologies has launched a $200 million public offering alongside a $90 million strategic investment from Medtronic, aiming to accelerate its DurAVR heart valve clinical trials and manufacturing expansion.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.

Anteris Technologies has updated the timetable for its Australian capital raising, delaying settlement to November 4 and the start of trading for new securities to November 5. The company also highlights restrictions on U.S. investors acquiring its CDIs.

Anteris Technologies has secured FDA approval to commence its pivotal PARADIGM clinical trial, testing its innovative DurAVR Transcatheter Heart Valve against established devices in patients with severe aortic stenosis.

Echo IQ reports a remarkable 153% increase in echocardiogram processing through its EchoSolv AS platform in the US, with a Mayo Clinic validation study nearing completion ahead of a critical FDA submission. The company is also advancing European market entry and strengthening its advisory team to accelerate global growth.